Musculoskeletal

Systemic lupus erythematosus: diagnosis and management

Clinical Overview and When to Suspect SLE

— Female:male ratio 9:1 in reproductive years; peak onset 15–44

— 3–4× higher prevalence and worse outcomes in Black, Hispanic, and Asian patients

— Strong familial clustering; ~10% have an affected first-degree relative

— Young woman with unexplained constitutional symptoms (fatigue, low-grade fever, weight loss) plus ≥2 organ systems (arthralgias + rash, pleurisy + cytopenias, proteinuria + alopecia)

— Recurrent miscarriages, unprovoked DVT/PE, or stroke in a young patient (overlap with antiphospholipid syndrome)

— New cytopenias (especially AIHA or ITP) without alternative cause

— Glomerulonephritis presenting as hypertension + hematuria + proteinuria in a young woman

— Drug-induced lupus pattern: hydralazine, procainamide, isoniazid, minocycline, TNF inhibitors, methimazole

Definition: Systemic lupus erythematosus is a chronic multisystem autoimmune disease driven by loss of tolerance to nuclear antigens, immune complex deposition, and type I interferon signaling, producing relapsing-remitting inflammation across skin, joints, kidneys, serosa, blood, and CNS.

Epidemiology that shapes pretest probability:

When to suspect on Step 3:

Diagnostic framework: 2019 EULAR/ACR criteria require a positive ANA ≥1:80 as entry criterion, then weighted clinical and immunologic domains totaling ≥10 points. Replaces older ACR 1997 criteria for board-style classification.

Step 3 management: SLE diagnosis is clinical plus serologic, not purely lab-based. Do not start immunosuppression on ANA alone—ANA has ~95% sensitivity but only ~50% specificity; 5–15% of healthy adults are ANA-positive at 1:80.

Board pearl: A positive ANA is necessary but never sufficient. The exam rewards candidates who pair ANA with dsDNA, anti-Smith, low complements (C3/C4), and a compatible clinical picture before committing to the diagnosis. Anti-Smith and anti-dsDNA are the most specific antibodies; dsDNA also tracks disease activity, especially renal flares.

Presentation Patterns and Key History

— Acute cutaneous lupus: malar/"butterfly" rash sparing nasolabial folds, photosensitive, no scarring

— Subacute cutaneous lupus: annular or psoriasiform photodistributed plaques; strongly anti-Ro/SSA-associated; often drug-induced (HCTZ, terbinafine, PPIs)

— Chronic cutaneous (discoid): scarring, hyperpigmented, scalp involvement → alopecia

— Oral/nasal ulcers (classically painless palatal), non-scarring alopecia, Raynaud phenomenon

— Sun exposure triggers

— Drug list (procainamide, hydralazine, minocycline, anti-TNF)

— Obstetric history (≥3 first-trimester losses or any ≥10-week loss → APS)

— Family history of autoimmunity

— Infection exposures (parvovirus, EBV mimic lupus)

Constitutional (90%): fatigue (most disabling symptom long-term), fever (must exclude infection in immunosuppressed lupus patient), weight loss, lymphadenopathy.

Mucocutaneous (80–90%):

Musculoskeletal (>90%): symmetric, non-erosive polyarthritis of small joints—mimics RA but without bony erosions. Jaccoud arthropathy = reducible deformities from ligamentous laxity. Tendon ruptures, avascular necrosis (especially after high-dose steroids).

Serositis: pleuritis with pleuritic chest pain, pericarditis (most common cardiac manifestation), occasionally peritonitis.

Renal (~50%): lupus nephritis—proteinuria, hematuria, hypertension, rising creatinine. Often asymptomatic until advanced; screen at every visit.

Neuropsychiatric: seizures, psychosis, cognitive dysfunction, stroke, peripheral neuropathy, aseptic meningitis, transverse myelitis.

Hematologic: AIHA (Coombs+), ITP, leukopenia/lymphopenia, antiphospholipid-driven thrombosis and pregnancy loss.

Key history to elicit:

Key distinction: SLE arthritis is non-erosive; RA is erosive. On hand films, lupus shows reducible ulnar deviation without joint-space destruction. Mixing these up is a classic distractor.

Board pearl: Painless oral ulcers and non-scarring alopecia are easily missed unless directly asked—both score points in EULAR/ACR criteria and are commonly tested as the "extra" criterion that clinches diagnosis.

Physical Exam Findings and Hemodynamic Assessment

— Malar erythema over cheeks/bridge of nose, sparing nasolabial folds (distinguishes from rosacea and seborrheic dermatitis, which involve them)

— Discoid plaques: erythematous, scaly, atrophic with follicular plugging; biopsy if uncertain

— Photodistributed rash on V of neck, dorsal arms

— Palatal/buccal ulcers—lift the tongue and inspect the hard palate

— Diffuse non-scarring alopecia; "lupus hair" = short, broken frontal hairs

— Periungual erythema, livedo reticularis (think APS overlap)

— Raynaud: triphasic color change of digits

— Symmetric synovitis of MCPs, PIPs, wrists, knees

— Reducible swan-neck deformities (Jaccoud) without erosions

— Tenderness over greater trochanter or groin → suspect AVN, especially with prior steroids

— Pleural/pericardial rubs; muffled heart sounds + pulsus paradoxus + elevated JVP → tamponade, a CCS emergency

— Libman-Sacks endocarditis: non-bacterial verrucous valvular vegetations, usually mitral; new murmur warrants TTE

— Hypertension as a sign of lupus nephritis or renal artery thrombosis (APS)

— Tachycardia disproportionate to fever → consider PE in APS patient

— Focal deficits (stroke), cognitive screen abnormalities, cranial neuropathies

— Psychosis or new seizure in young woman without prior history is an SLE red flag

Skin and mucosa:

Musculoskeletal:

Cardiopulmonary and hemodynamics:

Neurologic:

Abdominal: splenomegaly, mesenteric vasculitis tenderness, ascites from serositis or nephrotic syndrome.

CCS pearl: In a hypotensive lupus patient with elevated JVP and distant heart sounds, immediate bedside echo and pericardiocentesis precede any rheumatology workup. Stabilize hemodynamics first; serologies can wait.

Board pearl: The malar rash spares the nasolabial folds—rosacea involves them and has telangiectasias and pustules. This single distinction is asked repeatedly.

Diagnostic Workup — Initial Labs, Imaging, Biomarkers

— ANA by IFA on HEp-2 cells at ≥1:80 — entry criterion for 2019 EULAR/ACR

— CBC with differential: cytopenias (AIHA, leukopenia <4000, lymphopenia <1000, thrombocytopenia <100k)

— Comprehensive metabolic panel: creatinine, albumin

— Urinalysis with microscopy + urine protein-to-creatinine ratio (UPCR): proteinuria >0.5 g/day, hematuria, RBC/cellular casts = active nephritis

— ESR (often elevated) and CRP (often normal or mildly elevated—disproportionately low CRP is classic; high CRP suggests infection or serositis)

— LFTs, LDH, haptoglobin, reticulocyte count, direct Coombs if anemia

— Anti-dsDNA: ~70% sensitive, highly specific; correlates with nephritis activity

— Anti-Smith: ~30% sensitive but >95% specific—pathognomonic when present

— Anti-Ro/SSA, anti-La/SSB: sicca, subacute cutaneous, neonatal lupus risk

— Anti-U1-RNP: high titers → MCTD

— Antiphospholipid panel: lupus anticoagulant, anti-cardiolipin IgG/IgM, anti-β2-glycoprotein I IgG/IgM

— C3 and C4: low complements indicate active disease/consumption

— CXR for pleural effusion, infiltrates

— TTE for pericardial effusion, Libman-Sacks, pulmonary hypertension

— Hand X-rays: non-erosive arthropathy

— MRI brain for neuropsychiatric SLE

Tier 1 screening labs (order at first suspicion):

Tier 2 specific autoantibodies (if ANA positive):

Imaging when clinically indicated:

Step 3 management: A patient with arthritis + malar rash + ANA 1:640 + anti-dsDNA + low C3/C4 + proteinuria meets criteria—you do not need a kidney biopsy to diagnose SLE, but you DO need one to classify lupus nephritis and guide immunosuppression.

Board pearl: CRP normal but ESR sky-high in a flaring lupus patient is a classic exam clue. A rising CRP in a known SLE patient should push you toward infection rather than flare until proven otherwise—particularly in immunosuppressed patients.

Diagnostic Workup — Advanced and Confirmatory Studies

— Indications: proteinuria >500 mg/day, active urinary sediment (RBC casts, dysmorphic RBCs), unexplained rise in creatinine

— ISN/RPS classification drives therapy:

— Class I: minimal mesangial — no immunosuppression

— Class II: mesangial proliferative — usually no immunosuppression

— Class III (focal) and IV (diffuse) proliferative: aggressive immunosuppression required

— Class V: membranous, nephrotic-range proteinuria — immunosuppression if persistent

— Class VI: advanced sclerosis — supportive/transplant evaluation

— Activity and chronicity indices guide prognosis

— Discoid or atypical rash: shows interface dermatitis, perivascular lymphocytic infiltrate

— Direct immunofluorescence ("lupus band test"): IgG/IgM/C3 at dermoepidermal junction

— MRI brain with/without contrast (small vessel ischemia, white matter lesions)

— LP to exclude infection; CSF may show elevated protein, mild pleocytosis

— EEG if seizures; neuropsychiatric testing for cognitive complaints

— Two positive tests ≥12 weeks apart (lupus anticoagulant, anti-cardiolipin, or anti-β2GP-I)

— Triple-positive carries the highest thrombotic risk

Renal biopsy (the most important confirmatory test in SLE):

Skin biopsy:

Neurologic workup for NPSLE:

Antiphospholipid confirmation:

Disease activity tools (less tested but referenced): SLEDAI-2K, BILAG; anti-dsDNA titers and C3/C4 are the practical longitudinal markers.

Key distinction: A single positive lupus anticoagulant during acute illness or anticoagulation is not diagnostic of APS—repeat at ≥12 weeks. Don't commit a patient to lifelong anticoagulation on one transient result.

Board pearl: When a stem describes nephrotic-range proteinuria with normal complements and no active sediment in a lupus patient, think Class V (membranous) lupus nephritis. Active sediment + low C3/C4 + rising dsDNA points to Class III or IV.

Risk Stratification and First-Line Management Logic

— Mild: constitutional symptoms, skin, arthritis, mild serositis, mild cytopenias

— Moderate: significant serositis, moderate cytopenias, severe skin disease

— Severe/organ-threatening: lupus nephritis (Class III/IV/V), neuropsychiatric SLE, severe AIHA/ITP (<20k), alveolar hemorrhage, mesenteric vasculitis, myocarditis, catastrophic APS

— Hydroxychloroquine 5 mg/kg/day actual body weight (max 400 mg)

— Reduces flares, prevents organ damage, improves survival, reduces thrombosis, safe in pregnancy

— Baseline + annual ophthalmologic exam after 5 years (or sooner if risk factors) for retinal toxicity

— Sun protection: SPF 50+, broad-brimmed hats, avoid peak UV

— Vaccinations (inactivated only if immunosuppressed): annual flu, PCV20/PCV15+PPSV23, HPV, shingles (recombinant), COVID-19

— Cardiovascular risk reduction: aggressive BP, lipid, glucose control—SLE confers RR ~2× for MI, ~8× in young women

— Bone health: calcium, vitamin D; DEXA if chronic steroid use

— Mild → HCQ ± low-dose prednisone (≤7.5 mg) ± topical steroids

— Moderate → add methotrexate, azathioprine, or belimumab

— Severe → high-dose glucocorticoids + mycophenolate mofetil or cyclophosphamide, ± belimumab or anifrolumab

Organ-based severity drives therapy. Stratify by:

Universal background therapy for ALL SLE patients (unless contraindicated):

Therapeutic escalation logic:

Step 3 management: The single highest-yield intervention is starting hydroxychloroquine in every SLE patient. Failure to prescribe HCQ is a frequent board "wrong answer pattern"—patients on HCQ have lower mortality, fewer flares, and better pregnancy outcomes.

Board pearl: Goal prednisone dose at maintenance is ≤5 mg/day to minimize cumulative steroid damage (osteoporosis, AVN, diabetes, infection). The exam favors steroid-sparing strategies via early addition of immunosuppressants or biologics.

Pharmacotherapy — First-Line Drug Regimens by Manifestation

— Topical for cutaneous disease

— Intra-articular for monoarthritis

— Low-dose oral (prednisone 5–10 mg) for mild systemic flares

— Moderate (0.5 mg/kg) for serositis, significant cytopenias

— Pulse IV methylprednisolone 500–1000 mg × 3 days for organ-threatening flare (nephritis, NPSLE, alveolar hemorrhage)

— Mycophenolate mofetil 2–3 g/day (preferred in Black/Hispanic patients, women of reproductive age planning future pregnancy with washout) OR

— Low-dose IV cyclophosphamide (Euro-Lupus regimen: 500 mg q2 weeks × 6 doses)

— Plus high-dose steroids tapered rapidly

— Adjunctive: belimumab or voclosporin (calcineurin inhibitor) added to MMF improves renal response

— Belimumab (anti-BLyS): moderate SLE, lupus nephritis adjunct

— Anifrolumab (anti-IFNAR1): moderate-severe skin/joint disease

— Rituximab: off-label for refractory cytopenias, nephritis

Hydroxychloroquine (foundation): 5 mg/kg actual body weight; check G6PD only if Mediterranean/African ancestry with hemolysis risk; warn about retinal toxicity, QT prolongation.

Glucocorticoids:

Lupus nephritis (Class III/IV ± V) induction:

Maintenance (after induction): MMF 1–2 g/day or azathioprine 2 mg/kg/day for ≥3 years.

Neuropsychiatric SLE: pulse steroids + cyclophosphamide for inflammatory etiologies; anticoagulation if thrombotic/APS-driven.

Severe AIHA/ITP: high-dose steroids; rituximab or IVIG for refractory.

Biologics:

Drugs to AVOID or use cautiously: sulfa antibiotics (flare trigger), estrogen-containing contraceptives in APS-positive or active disease (use progestin-only or IUD).

Step 3 management: For Class IV lupus nephritis in a 28-year-old woman who wants children, MMF for induction is preferred over cyclophosphamide (cyclophosphamide carries ovarian failure risk; co-administer leuprolide if used). Counsel washout: MMF teratogenic—switch to azathioprine ≥6 weeks before conception.

Board pearl: Azathioprine, hydroxychloroquine, and low-dose prednisone are the pregnancy-compatible trio. MMF, methotrexate, and cyclophosphamide are teratogenic.

Expanded Pharmacology and Refractory Disease Management

— Failure of MMF or cyclophosphamide induction in lupus nephritis (no ≥25% proteinuria reduction at 3 months, no ≥50% at 6 months) → switch agents, add voclosporin or belimumab, consider rituximab

— Refractory cutaneous disease: add methotrexate, belimumab, anifrolumab, or thalidomide (last-line, teratogenic, neuropathy risk)

— Refractory arthritis: methotrexate, leflunomide, belimumab

— Voclosporin: 23.7 mg BID; monitor BP and creatinine (calcineurin nephrotoxicity); approved adjunct for lupus nephritis

— Belimumab: IV monthly or SC weekly; monitor for infection, depression/suicidality; avoid live vaccines

— Anifrolumab: IV q4 weeks; increased herpes zoster risk—give recombinant zoster vaccine before initiation

— Rituximab: assess hepatitis B status (HBsAg, anti-HBc) before infusion; risk of reactivation and PML

— Primary prevention if triple-positive: low-dose aspirin + hydroxychloroquine

— Secondary prevention after thrombosis: warfarin INR 2–3 (lifelong); DOACs inferior in triple-positive APS—do not use

— Obstetric APS: prophylactic LMWH + low-dose aspirin throughout pregnancy

— NSAIDs for arthralgia (caution with renal disease)

— Topical tacrolimus for facial discoid lesions

— Statins per ASCVD risk; ACE/ARB for proteinuria (renoprotection + BP)

Treatment-refractory pathways:

Adjunctive therapies and monitoring details:

Antiphospholipid syndrome management within SLE:

Symptom-directed adjuncts:

CCS pearl: For a hospitalized lupus nephritis flare, sequence orders as: admit → IV methylprednisolone pulse → renal biopsy if not done → start MMF or cyclophosphamide → ACE inhibitor for proteinuria → PCP prophylaxis with TMP-SMX → calcium/vit D → DVT prophylaxis → rheumatology and nephrology consults → counsel contraception.

Board pearl: PCP (Pneumocystis jirovecii) prophylaxis with TMP-SMX is indicated when prednisone ≥20 mg/day for ≥4 weeks combined with another immunosuppressant—however, sulfa drugs can flare lupus; dapsone or atovaquone are alternatives if sulfa-intolerant.

Special Populations — Elderly and Renal/Hepatic Impairment

— More serositis, pulmonary involvement, sicca, and constitutional symptoms

— Less nephritis, less malar rash, less CNS disease

— Higher rates of anti-Ro/SSA positivity

— Often misdiagnosed initially as RA, polymyalgia rheumatica, or malignancy

— Drug-induced lupus more common in this age group—review meds first

— Higher infection risk with immunosuppression → lower steroid thresholds, earlier steroid-sparing agents

— Cumulative comorbidity (CAD, osteoporosis, diabetes) amplifies steroid harm

— Polypharmacy and drug-drug interactions (HCQ-QT, MMF-PPI absorption)

— Screen carefully for malignancy mimicking SLE (lymphoma, paraneoplastic)

— Adjust MMF and cyclophosphamide doses; cyclophosphamide reduce by 25–50% if CrCl <50

— Avoid NSAIDs in CKD stage ≥3

— ACEi/ARB titrated to maximally tolerated dose for proteinuria; monitor K+ and creatinine

— Hydroxychloroquine: same dose in CKD but consider levels if available; retinal toxicity risk higher

— ESRD lupus patients: SLE activity often diminishes on dialysis; many tolerate reduced immunosuppression

— Renal transplant: outcomes equivalent to other causes; recurrence rare; continue HCQ

— Azathioprine—reduce dose, monitor TPMT and LFTs (idiosyncratic hepatotoxicity)

— Methotrexate contraindicated in significant hepatic disease; avoid alcohol

— MMF generally safe in hepatic impairment

— Check hepatitis B/C before any immunosuppression

Late-onset SLE (>50 years at diagnosis, ~10–20% of cases):

Considerations in older patients:

Renal impairment management:

Hepatic impairment:

Step 3 management: Before initiating biologics or cytotoxic therapy, screen for latent TB (IGRA), hepatitis B (HBsAg, anti-HBc, anti-HBs), hepatitis C, and HIV. Treat latent TB with isoniazid before immunosuppression.

Board pearl: A 65-year-old woman with new pleuritis, positive ANA, anti-histone antibodies, and a recent start of hydralazine for hypertension has drug-induced lupus—stop the drug, expect resolution in weeks to months. Drug-induced lupus rarely involves kidneys or CNS and is anti-dsDNA negative.

Special Populations — Pregnancy and Pediatrics

— Recommend pregnancy only when SLE has been quiescent ≥6 months

— Active lupus nephritis or recent severe flare → defer pregnancy

— Switch teratogens before conception: MMF/methotrexate/cyclophosphamide → azathioprine, hydroxychloroquine, low-dose prednisone (≥6 weeks washout for MMF)

— Continue hydroxychloroquine throughout pregnancy—reduces flares, congenital heart block risk, and preeclampsia

— Flares (especially renal)—monitor monthly with UA, UPCR, complements, dsDNA

— Preeclampsia (4× higher); distinguishing from lupus nephritis flare is critical: flare → low C3/C4, rising dsDNA, active sediment; preeclampsia → normal complements, elevated uric acid, after 20 weeks

— Thrombosis if APS-positive

— Pregnancy loss, IUGR, preterm delivery

— Anti-Ro/SSA and anti-La/SSB → neonatal lupus: transient skin rash, cytopenias, and congenital complete heart block (often irreversible). Screen all SLE patients for anti-Ro/La; fetal echo weekly from 16–26 weeks if positive

— APS → recurrent miscarriage, stillbirth

— More severe at presentation: higher rates of nephritis, NPSLE, hematologic disease

— More aggressive induction therapy often required

— Growth, schooling, mental health, transition-of-care planning essential

— Greater cumulative damage over lifetime—aggressive HCQ, steroid-sparing, and CV risk reduction from diagnosis

Preconception planning is mandatory:

Maternal risks during pregnancy:

Fetal/neonatal risks:

Pregnancy-compatible regimen: HCQ + azathioprine + low-dose prednisone if needed; aspirin 81 mg from <16 weeks for preeclampsia prevention; LMWH + ASA if APS.

Pediatric SLE (~15–20% of cases, onset <18 years):

Step 3 management: A 19-year-old SLE patient transitioning from pediatric to adult care needs a structured handoff: medication reconciliation, contraception counseling, mental health screen, ophthalmology, vaccine update, and explicit transfer of records and follow-up scheduling.

Board pearl: Anti-Ro/SSA positive mother + fetal bradycardia at 20 weeks gestation = congenital heart block from neonatal lupus. Treatment options (dexamethasone, IVIG, hydroxychloroquine prophylaxis) are limited and largely preventive.

Complications and Adverse Outcomes

— Accelerated atherosclerosis; MI risk ~8× in young women with SLE

— Libman-Sacks endocarditis → embolic stroke

— Pericarditis, myocarditis, pulmonary hypertension

— Aggressive lipid, BP, glucose, and smoking control are mandatory

— Immunosuppression + complement deficiencies → encapsulated organisms (Strep pneumo, Neisseria, Haemophilus)

— Opportunistic: PCP, CMV, herpes zoster, candida, Nocardia

— Distinguish flare from infection: CRP elevated → infection; ESR + dsDNA + low C3/C4 → flare

— HCQ retinopathy, cardiomyopathy (long-term)

— Steroid Cushing, diabetes, cataracts, glaucoma, AVN

— MMF GI intolerance, cytopenias, infections

— Cyclophosphamide hemorrhagic cystitis, bladder cancer, infertility

Cardiovascular (leading cause of late mortality):

Renal: ESRD in 10–20% of lupus nephritis despite therapy; HTN; recurrent flares.

Infection (leading cause of early mortality):

Hematologic: severe AIHA, TTP-like microangiopathy, catastrophic APS.

Pulmonary: pleuritis, shrinking lung syndrome, ILD, alveolar hemorrhage, PE.

Musculoskeletal: osteoporosis (steroids), avascular necrosis (often femoral head; suspect with new groin pain after steroids), myopathy.

Neuropsychiatric: stroke, seizures, cognitive decline, psychosis, depression, peripheral neuropathy.

Malignancy: increased non-Hodgkin lymphoma risk; cervical dysplasia/HPV (immunosuppression)—annual Pap with HPV co-testing.

Reproductive: premature ovarian failure (cyclophosphamide), pregnancy complications.

Treatment-related toxicities:

Step 3 management: New groin or hip pain in any SLE patient on steroids → MRI hip (most sensitive for early AVN; plain films are insensitive early). Refractory or advanced AVN may need core decompression or hip arthroplasty.

Board pearl: Distinguishing flare vs infection in a febrile lupus patient is the most commonly tested decision. Procalcitonin and CRP rise with infection; complements drop and dsDNA rises with flare. When in doubt, treat for both: empiric antibiotics + cultures, then taper based on workup.

When to Escalate Care — ICU, Consult, Inpatient Triage

— Diffuse alveolar hemorrhage (hemoptysis, hypoxia, dropping Hgb, bilateral infiltrates)

— Catastrophic antiphospholipid syndrome (≥3 organ thromboses in <1 week)

— Pulmonary embolism with hemodynamic compromise

— Cardiac tamponade

— Severe NPSLE: status epilepticus, coma, severe psychosis

— Severe AIHA (Hgb <6) or ITP with bleeding

— TTP-like microangiopathy

— Septic shock in immunosuppressed lupus patient

— Active lupus nephritis with rapidly rising creatinine

— New significant proteinuria requiring biopsy and IV therapy

— Suspected infection in patient on multiple immunosuppressants

— Severe serositis with hemodynamic effects

— New thrombosis requiring anticoagulation initiation

— Refractory pain, intractable vasculitis symptoms

— Rheumatology for all new SLE diagnoses and any flare

— Nephrology for proteinuria >500 mg/day, hematuria with casts, rising creatinine; co-manage biopsy and immunosuppression

— Neurology for NPSLE workup

— Cardiology for pericarditis, Libman-Sacks, pulmonary hypertension

— Maternal-fetal medicine for any SLE pregnancy

— Hematology for severe cytopenias, APS

— Ophthalmology annually after 5 years of HCQ (sooner if risk factors)

Immediate ICU triage:

Inpatient admission criteria:

Specialist consultations:

CCS pearl: For a lupus patient admitted with new dyspnea, hemoptysis, and falling hemoglobin: stat CXR/CT, type and screen, two large-bore IVs, pulse methylprednisolone 1 g IV daily × 3 days, consult pulmonology and rheumatology, initiate plasmapheresis if alveolar hemorrhage confirmed, hold anticoagulation, ICU admission. Alveolar hemorrhage mortality exceeds 50%—act fast.

Board pearl: Always have a low threshold for infection workup before attributing new symptoms to flare. Blood cultures, urine cultures, chest imaging, and broad-spectrum antibiotics first, then immunosuppression adjustment second.

Key Differentials — Same-Category (Connective Tissue and Autoimmune)

— Symmetric polyarthritis of small joints—shared with SLE

— Erosive disease on imaging, rheumatoid factor and anti-CCP positive

— ANA can be positive (~30%) but anti-dsDNA negative

— No malar rash, photosensitivity, or serositis as primary features

— Sicca symptoms (dry eyes, dry mouth), parotid enlargement

— Anti-Ro/SSA, anti-La/SSB positive (also seen in SLE)

— Increased lymphoma risk

— Can overlap with SLE; positive Schirmer test, lip biopsy

— Features of SLE + scleroderma + polymyositis

— High-titer anti-U1-RNP, often without anti-dsDNA or anti-Smith

— Raynaud, puffy hands, myositis prominent

— Skin thickening, Raynaud, sclerodactyly, telangiectasias

— Anti-centromere (limited/CREST) or anti-Scl-70 (diffuse)

— Renal crisis (treat with ACE inhibitor)

— Proximal muscle weakness, Gottron papules, heliotrope rash

— Elevated CK, anti-Jo-1, anti-Mi-2

— Granulomatosis with polyangiitis: sinus, lung, kidney—anti-PR3

— Microscopic polyangiitis: glomerulonephritis, pulmonary hemorrhage—anti-MPO

— Can mimic SLE nephritis; complements are normal in ANCA vasculitis (vs low in SLE)

— Thrombosis and pregnancy loss without other SLE features

— Same antibody panel; no ANA-driven multisystem disease

— Quotidian fever, salmon-colored rash, arthritis, ferritin >1000

— ANA and RF typically negative

Rheumatoid arthritis:

Sjögren syndrome:

Mixed connective tissue disease (MCTD):

Systemic sclerosis:

Dermatomyositis/polymyositis:

Vasculitides (especially ANCA-associated):

Primary antiphospholipid syndrome:

Adult-onset Still disease:

Key distinction: SLE typically has low complements; most other autoimmune diseases (RA, Sjögren, dermatomyositis, ANCA vasculitis) do not consume complement. Low C3/C4 + active urine sediment in young woman → think lupus nephritis until proven otherwise.

Board pearl: Overlap syndromes are common—a patient may meet criteria for both SLE and Sjögren or both SLE and RA ("rhupus"). Document each diagnosis; treatment principles overlap heavily around HCQ + methotrexate ± biologics.

Key Differentials — Other-Category Mimics

— Parvovirus B19: arthralgias, malar-like rash, cytopenias, transient ANA—resolves in weeks; check parvovirus IgM

— EBV/CMV: fatigue, lymphadenopathy, cytopenias, ANA can transiently turn positive

— HIV: lymphopenia, thrombocytopenia, arthralgias, false-positive autoantibodies—always check HIV in new "lupus"

— Hepatitis B/C: cryoglobulinemia, vasculitis, arthralgias, positive ANA

— Endocarditis: fevers, cytopenias, glomerulonephritis, embolic phenomena—blood cultures, TEE

— Tuberculosis: constitutional symptoms, serositis

— Lymphoma: fevers, weight loss, cytopenias, lymphadenopathy—CT, biopsy

— Paraneoplastic syndromes: dermatomyositis-like rash, arthritis

— Multiple myeloma: anemia, renal disease, bone pain

— Anti-histone antibodies (>95%), anti-dsDNA usually negative, normal complements

— Triggers: procainamide, hydralazine, isoniazid, minocycline, anti-TNF agents, methimazole, terbinafine, PPIs

— Resolves with drug discontinuation

— Rarely involves kidneys or CNS

— Diffuse pain, fatigue, sleep disturbance without inflammation

— Normal labs, normal exam

— Can coexist with SLE (~20%) and confound flare assessment

Infections that mimic SLE:

Malignancies:

Drug-induced lupus:

Fibromyalgia:

Thyroid disease: Hashimoto and Graves often coexist with SLE; check TSH in fatigue workup.

Sarcoidosis: multisystem granulomatous disease, hilar lymphadenopathy, hypercalcemia, ACE elevation.

Thrombotic microangiopathies: TTP, HUS, malignant hypertension, scleroderma renal crisis—can mimic SLE flare with cytopenias and renal failure. Smear for schistocytes; ADAMTS13 for TTP.

Step 3 management: Before committing to SLE diagnosis and immunosuppression, screen for HIV, hepatitis B, hepatitis C, and TB. Missing an underlying infection and giving steroids is a high-yield, dangerous error.

Board pearl: New "lupus" with anti-histone antibodies, normal complements, negative anti-dsDNA, and recent hydralazine or procainamide start = drug-induced lupus. Stop the offending drug; do not start chronic immunosuppression.

Secondary Prevention, Discharge Meds, Long-Term Plan

— Hydroxychloroquine: lifelong unless toxicity

— Sun protection education at every visit

— Vaccinations: annual influenza (inactivated), pneumococcal (PCV20 or PCV15+PPSV23), HPV, recombinant zoster (≥19 if immunosuppressed), Tdap, hepatitis B if non-immune, COVID-19 boosters. Avoid live vaccines (MMR, varicella, yellow fever, intranasal flu) if on significant immunosuppression

— Smoking cessation: reduces flare risk and CV events; smoking reduces HCQ efficacy

— BP <130/80; ACEi/ARB first if proteinuria

— Statin per ASCVD risk; lower threshold given accelerated atherosclerosis

— Diabetes screening annually

— Aspirin 81 mg if APS-positive or established ASCVD

— Calcium 1000–1200 mg, vitamin D 800–2000 IU

— DEXA baseline if starting steroids ≥5 mg × 3 months; repeat q1–2 years

— Bisphosphonate if steroids ≥7.5 mg × ≥3 months and fracture risk elevated (avoid in pregnancy planning)

— Contraception counseling: progestin-only or copper IUD preferred if APS-positive or active disease; combined OCPs acceptable only if APS-negative and stable

— Preconception counseling, medication switching, anti-Ro/La and APS screening

— Annual Pap with HPV (cervical dysplasia risk)

— Age-appropriate breast, colon, lung screening

— Increased lymphoma vigilance

— HCQ continued, prednisone taper plan written explicitly, steroid-sparing agent dosing, PCP prophylaxis if applicable, calcium/vit D, BP and proteinuria monitoring plan, contraception, vaccinations updated, rheumatology and primary care follow-up scheduled

Universal long-term measures:

Cardiovascular risk reduction:

Bone health:

Reproductive health:

Cancer screening:

Discharge medication checklist after flare admission:

Step 3 management: Write the prednisone taper on the discharge summary with specific dates and decrements (e.g., "60 mg × 2 weeks, then 40 mg × 2 weeks, then decrease by 5 mg every 2 weeks to 5 mg maintenance"). Ambiguous tapers are a top transition-of-care safety failure.

Board pearl: Lifelong HCQ continuation, even in remission, is the single most powerful long-term mortality-reduction intervention in SLE.

Follow-Up, Monitoring Parameters, Rehab/Counseling

— Newly diagnosed or recently flaring: every 1–3 months

— Stable, on maintenance therapy: every 3–6 months

— Long-stable, low-dose monotherapy: every 6–12 months

— Symptom review (rashes, joints, sicca, alopecia, oral ulcers, chest pain, neuro symptoms)

— BP, weight, skin exam, joint exam

— Urinalysis with microscopy + UPCR at every visit (catches subclinical nephritis)

— CBC, creatinine, LFTs (if on MMF/AZA/MTX)

— Anti-dsDNA and C3/C4 every 3–6 months to track activity

— Medication adherence and side effects review

— HCQ: baseline + annual eye exam from year 5 (or earlier with renal disease, high dose, tamoxifen use)

— MMF: CBC monthly initially, then quarterly; GI tolerance

— Azathioprine: TPMT or NUDT15 baseline; CBC and LFTs every 2–4 weeks initially, then quarterly

— Methotrexate: CBC, LFTs every 2–4 weeks initially; folic acid 1 mg daily

— Cyclophosphamide: CBC, UA (hemorrhagic cystitis), bladder cancer surveillance long-term

— Belimumab/anifrolumab: infection screen, mental health (belimumab)

— Lipids, fasting glucose/HbA1c, BP, DEXA per indication

— Pap with HPV co-testing

— Skin cancer screening if discoid lupus or long-term immunosuppression

— Influenza, COVID, other vaccines as scheduled

— Pacing strategies for fatigue (cardinal disabling symptom)

— Sleep hygiene, exercise (aerobic + resistance), Mediterranean-style diet

— Mental health screening (depression and anxiety prevalent)

— Support groups, patient education

— Physical therapy for arthritis, occupational therapy for hand function

Outpatient follow-up cadence:

Each visit checklist:

Drug-specific monitoring:

Annual screenings:

Patient counseling and rehabilitation:

Step 3 management: A stable SLE patient with new 2+ proteinuria on dipstick at routine visit requires immediate UPCR, microscopy for casts, complements, dsDNA, and prompt rheumatology/nephrology contact—do not wait for the next scheduled visit.

Board pearl: Rising anti-dsDNA + falling C3/C4 often precede clinical flare by weeks—act on serologic flare with closer monitoring and pre-emptive therapy adjustment.

Ethical, Legal, and Patient Safety Considerations

— Disclose infection risk, malignancy risk (cyclophosphamide → bladder cancer; long-term immunosuppression → skin cancer, lymphoma)

— Fertility implications of cyclophosphamide—document offer of fertility preservation (oocyte/embryo cryopreservation, leuprolide for ovarian protection)

— Teratogenicity of MMF, MTX, cyclophosphamide—patients of reproductive potential need explicit counseling and contraception documentation before prescribing

— Pregnancy is not contraindicated in well-controlled SLE; respect patient autonomy

— Provide unbiased risk counseling; document discussion of maternal and fetal risks

— Avoid coercive language; involve MFM early

— NPSLE can impair decision-making; assess capacity at each major decision

— Use surrogate decision-makers and advance directives proactively

— Psychiatry collaboration for psychosis/severe depression—differentiate from steroid psychosis (often dose-dependent, reversible)

— Pediatric-to-adult transition: structured handoff, medication reconciliation, contraception

— Hospital discharge: explicit prednisone taper schedule, immunosuppressant dosing, infection precautions, follow-up appointment scheduled before discharge

— Inter-specialty handoffs: rheumatology, nephrology, OB, primary care must each have clear roles—written care plan reduces error

— Black, Hispanic, and Asian patients have worse SLE outcomes—structural factors include access delays, insurance gaps, social determinants

— Step 3 increasingly tests recognition of disparities and advocacy: arrange social work, medication assistance, transportation, language services

— Document but maintain confidentiality around reproductive decisions in adolescents per state law

— Driving safety after seizure (NPSLE)—state-specific reporting laws apply

Informed consent for immunosuppression:

Reproductive rights and counseling:

Capacity and neuropsychiatric SLE:

Transitions of care (high-risk for SLE):

Health equity:

Mandatory reporting and confidentiality:

Step 3 management: A 24-year-old woman with active Class IV lupus nephritis needs cyclophosphamide; her boyfriend objects to contraception. The clinician's duty is to the patient: confidential counseling, offer the full contraception menu (including LARC), document teratogenicity discussion, and do not initiate cyclophosphamide without reliable contraception in place.

Board pearl: Steroid-induced psychosis vs NPSLE psychosis is a frequent ethics/safety stem—steroid psychosis improves with dose reduction; NPSLE worsens. Document capacity assessment.

High-Yield Associations and Rapid-Fire Facts

— Anti-dsDNA → nephritis, activity marker

— Anti-Smith → most specific for SLE

— Anti-Ro/SSA → subacute cutaneous lupus, neonatal lupus, congenital heart block, Sjögren

— Anti-La/SSB → neonatal lupus, Sjögren

— Anti-U1-RNP → MCTD

— Anti-histone → drug-induced lupus

— Anti-ribosomal P → NPSLE (psychosis)

— Antiphospholipid → thrombosis, pregnancy loss

— Low C3 + low C4 → active SLE, especially nephritis

— Normal complements + active disease → consider non-renal flare or different diagnosis

— Hereditary C1q, C2, C4 deficiency → strong SLE predisposition

— Malar (acute) spares nasolabial folds

— Discoid (chronic) scars

— Subacute cutaneous: photo-distributed annular plaques, anti-Ro

— Early (<5 years): infection and active disease

— Late (>5 years): cardiovascular disease and malignancy

Antibody-disease pairings:

Complement clues:

Rash patterns:

Renal triad: proteinuria + hematuria + RBC casts → glomerulonephritis → biopsy.

Drug triggers for drug-induced lupus: PHIM-Q mnemonic—Procainamide, Hydralazine, Isoniazid, Minocycline, Quinidine (also methyldopa, anti-TNFs, terbinafine, PPIs, methimazole).

Pregnancy-safe meds: HCQ, azathioprine, low-dose prednisone, certolizumab, LMWH, aspirin.

Pregnancy-unsafe meds: MMF, MTX, cyclophosphamide, warfarin (first trimester), ACEi/ARB (second/third trimester).

Mortality bimodal pattern:

HCQ retinopathy risk factors: dose >5 mg/kg, duration >5 years, renal impairment, tamoxifen use, preexisting retinal disease.

Lupus anticoagulant paradox: prolongs aPTT in vitro (does not correct with mixing) but causes thrombosis in vivo.

CRP pattern: disproportionately low in active SLE; rises with infection or serositis.

Board pearl: Anti-ribosomal P antibodies are uniquely associated with lupus psychosis—a high-yield, low-prevalence association that distinguishes itself on the exam.

Board Question Stem Patterns

— Young Black woman with fatigue, arthralgias, malar rash, proteinuria, low C3/C4, anti-dsDNA positive → diagnose SLE with lupus nephritis; next step = renal biopsy for class, then induction therapy.

— Lupus patient on prednisone 60 mg for 2 months presents with fever, dry cough, hypoxia, bilateral interstitial infiltrates → Pneumocystis jirovecii pneumonia; treat with TMP-SMX, add prophylaxis going forward.

— 28-year-old woman with three first-trimester miscarriages and a DVT → antiphospholipid syndrome; check lupus anticoagulant, anti-cardiolipin, anti-β2GP-I twice ≥12 weeks apart; warfarin INR 2–3 lifelong, not DOACs.

— Pregnant lupus patient on MMF asking when to switch → switch to azathioprine ≥6 weeks before conception; continue HCQ.

— 65-year-old with new arthralgias, pleuritis, positive ANA and anti-histone, recently started hydralazine → drug-induced lupus; discontinue hydralazine.

— SLE patient on chronic prednisone develops new groin pain, normal X-ray → MRI hip for avascular necrosis.

— Newborn with bradycardia and complete heart block, mother with anti-Ro positivity → neonatal lupus.

— Lupus patient with new psychosis, anti-ribosomal P positive → NPSLE psychosis; differentiate from steroid psychosis by dose-response and timing.

— Febrile lupus patient with rising CRP, normal complements, stable dsDNA → think infection, not flare; culture, image, empiric antibiotics.

— Class IV lupus nephritis, 30-year-old woman wanting children → MMF preferred over cyclophosphamide for induction; counsel teratogenicity and contraception.

— Patient with malar rash sparing nasolabial folds vs. rash involving nasolabial folds with telangiectasias and pustules → SLE vs. rosacea.

— Lupus patient with shortness of breath, hemoptysis, falling Hgb, bilateral infiltrates → alveolar hemorrhage; ICU, pulse steroids, plasmapheresis.

Classic stems and what they're testing:

Step 3 management: Recognize stem keywords—"sparing nasolabial folds," "RBC casts," "low C3/C4," "anti-Smith," "anti-histone + new drug," "anti-Ro + pregnancy"—each triggers a specific next-best-step decision tree.

Board pearl: When the stem gives you a flare-vs-infection ambiguity, the highest-yield answer is to investigate and cover for both simultaneously, never to immediately escalate immunosuppression alone.

One-Line Recap

SLE is a multisystem, ANA-driven autoimmune disease whose backbone of management is lifelong hydroxychloroquine, organ-directed immunosuppression for severe disease (especially biopsy-classified lupus nephritis), aggressive cardiovascular and infection risk reduction, and meticulous reproductive and transition-of-care planning.

Diagnosis recap: Positive ANA ≥1:80 is the entry criterion; clinch with anti-dsDNA, anti-Smith, low C3/C4, plus compatible multisystem clinical features per 2019 EULAR/ACR criteria. Renal biopsy classifies lupus nephritis and guides therapy.

Treatment recap: Hydroxychloroquine for everyone, glucocorticoids tapered aggressively to minimize cumulative damage, MMF or cyclophosphamide induction for Class III/IV/V nephritis with adjunctive belimumab or voclosporin, biologics (belimumab, anifrolumab) for moderate-severe non-renal disease, and warfarin INR 2–3 for thrombotic APS.

Special populations recap: In pregnancy, continue HCQ, switch to azathioprine, add aspirin, screen anti-Ro/La and APS, and monitor for preeclampsia versus nephritis flare; in drug-induced lupus, identify and stop the offending agent (hydralazine, procainamide, isoniazid, minocycline, anti-TNF).

Long-term recap: Track activity with anti-dsDNA and complements, screen urine at every visit, vaccinate (avoid live vaccines if immunosuppressed), aggressively manage cardiovascular risk (the leading late mortality cause), provide annual ophthalmology after 5 years of HCQ, and structure transitions of care with explicit medication tapers and follow-up scheduling.

Board pearl: The two most commonly missed Step 3 actions are failing to prescribe hydroxychloroquine to every lupus patient and failing to distinguish flare from infection in the febrile immunosuppressed patient—master both and you will outperform on every SLE stem.